TY - JOUR
T1 - Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers
T2 - A Gynecologic Oncology Group study
AU - Farley, John
AU - Fuchiuji, Sartoru
AU - Darcy, Kathleen M.
AU - Tian, Chunqiao
AU - Hoskins, William J.
AU - McGuire, William P.
AU - Hanjani, Parviz
AU - Warshal, David
AU - Greer, Benjamin E.
AU - Belinson, Jerome
AU - Birrer, Michael J.
N1 - Funding Information:
This study was supported by National Cancer Institute grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517). The following Gynecologic Oncology Group (GOG) institutions participated in this study: University of Alabama School of Medicine, Abington Memorial Hospital, University of Rochester Medical Center, Walter Reed Army Medical Center, Wayne State University, Colorado Gynecologic Oncology Group P.C., University of California at Los Angeles, University of Washington, Milton S. Hershey Medical Center, Georgetown University Hospital, Wake Forest University School of Medicine, University of California Medical Center at Irvine, University of Kentucky, The Cleveland Clinic Foundation, Johns Hopkins Oncology Center, Eastern Pennsylvania Gyn/Onc Center, P.C., Cooper Hospital/University Medical Center, Columbus Cancer Council, University of Massachusetts Medical Center, University of Oklahoma, and Tacoma General Hospital, as well as the following resigned or terminated GOG member institutions: Oregon Health Sciences University, University of Southern California at Los Angeles and Stanford University Medical Center.
PY - 2009/6
Y1 - 2009/6
N2 - Objective(s): The Gynecologic Oncology Group (GOG) examined the association between ERBB2 amplification and clinical covariates, tumor response, disease status post-chemotherapy, progression-free survival (PFS), and overall survival (OS) in epithelial ovarian cancer (EOC). Methods: Women with suboptimally-resected, advanced stage EOC who participated in GOG-111, a multi-center randomized phase III trial of cyclophosphamide + cisplatin versus paclitaxel + cisplatin, and provided a tumor block through the companion protocol GOG-9404 were eligible. ERBB2 amplification was examined using fluorescence in situ hybridization (FISH) with probes for ERBB2 and the centromere of chromosome 17 (CEP17). Results: ERBB2 amplification, defined as > 2 copies of ERBB2/CEP17, was a rare event in EOC with 7% (9/133) of women exhibiting between 2.2 and 33.7 copies of ERBB2/CEP17, and was not associated with patient age, race, GOG performance status, stage, cell type, grade, measurable disease status, volume of ascites, tumor response or disease status post-chemotherapy. Women with > 2 verses ≤ 2 copies of ERBB2/CEP17 did not have a reduced risk of disease progression (hazard ratio [HR] = 0.56; 95% confidence interval [CI] = 0.27-1.16; p = 0.120) or death (HR = 0.57; 95% CI = 0.26-1.23; p = 0.152), and ERBB2 amplification was not an independent prognostic factor for PFS or OS. ERBB2 amplification, defined as > 4 copies of ERBB2/nuclei, was observed in 9% (12/133) of women with levels ranging from 4.2 to 49.2 copies of ERBB2/nuclei, and was associated with older age and volume of ascites, but not with the other clinical covariates or outcome. Conclusion(s): ERBB2 amplification is a rare event and has no predictive or prognostic value in suboptimally-resected, advanced stage EOC treated with platinum-based combination chemotherapy.
AB - Objective(s): The Gynecologic Oncology Group (GOG) examined the association between ERBB2 amplification and clinical covariates, tumor response, disease status post-chemotherapy, progression-free survival (PFS), and overall survival (OS) in epithelial ovarian cancer (EOC). Methods: Women with suboptimally-resected, advanced stage EOC who participated in GOG-111, a multi-center randomized phase III trial of cyclophosphamide + cisplatin versus paclitaxel + cisplatin, and provided a tumor block through the companion protocol GOG-9404 were eligible. ERBB2 amplification was examined using fluorescence in situ hybridization (FISH) with probes for ERBB2 and the centromere of chromosome 17 (CEP17). Results: ERBB2 amplification, defined as > 2 copies of ERBB2/CEP17, was a rare event in EOC with 7% (9/133) of women exhibiting between 2.2 and 33.7 copies of ERBB2/CEP17, and was not associated with patient age, race, GOG performance status, stage, cell type, grade, measurable disease status, volume of ascites, tumor response or disease status post-chemotherapy. Women with > 2 verses ≤ 2 copies of ERBB2/CEP17 did not have a reduced risk of disease progression (hazard ratio [HR] = 0.56; 95% confidence interval [CI] = 0.27-1.16; p = 0.120) or death (HR = 0.57; 95% CI = 0.26-1.23; p = 0.152), and ERBB2 amplification was not an independent prognostic factor for PFS or OS. ERBB2 amplification, defined as > 4 copies of ERBB2/nuclei, was observed in 9% (12/133) of women with levels ranging from 4.2 to 49.2 copies of ERBB2/nuclei, and was associated with older age and volume of ascites, but not with the other clinical covariates or outcome. Conclusion(s): ERBB2 amplification is a rare event and has no predictive or prognostic value in suboptimally-resected, advanced stage EOC treated with platinum-based combination chemotherapy.
KW - Carcinogenesis
KW - ERBB2
KW - FISH
KW - Gene amplification
KW - Ovary
UR - http://www.scopus.com/inward/record.url?scp=67349095676&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2009.02.009
DO - 10.1016/j.ygyno.2009.02.009
M3 - Article
C2 - 19272639
AN - SCOPUS:67349095676
SN - 0090-8258
VL - 113
SP - 341
EP - 347
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -